Bicara Therapeutics (BCAX)

• Market cap: $1.25B
• 1 day: -0.41%
• 5 days: -3.25%
• 1 month: 37.22%
• 3 months: 7.45%
• 6 months: 76.12%
• Year to date: 17.95%
• 1 year: 43.11%
• 5 years: -17.47%
• 10 years: -17.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.